GlassScriptPhysician profile
Phu H Nguyen
NPI 1801823778
$1,680.57
in general payments reported to CMS, 2019-2025
10 companies · $1,125 in 2025
The $1,125 reported for 2025 was more than what 82% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2022: $224 · 2023: $29.75 · 2024: $137 · 2025: $1,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,125 · Food and Beverage: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,125.00 |
| Food and Beverage | $166.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aroa Biosurgery Incorporated | $1,125.00 | 2025 | |
| Stryker Corporation | $133.38 | 2019-2022 | |
| Kerecis Limited | $116.59 | 2019-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Organogenesis INC. | $115.63 | 2022 | |
| Smith+Nephew, INC. | $46.96 | 2019 | |
| Convatec INC. | $41.17 | 2024 | |
| Nalu Medical, INC. | $29.75 | 2023 | Nalu Neurostimulation System |
| Melinta Therapeutics, LLC | $27.86 | 2019 | |
| Zimmer Biomet Holdings, INC. | $26.85 | 2019 | |
| Acell, INC. | $17.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phu Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.